bioRxiv Science⌕ Search

Biology subjects

Mighell, T.

Publications and source records attributed to Mighell, T..

3 recordsLinked to original sources

The genetic architecture of G-protein coupled receptor signaling

G protein-coupled receptors (GPCRs) are the largest family of human receptors and drug targets, but how the signaling properties of receptors are encoded in their sequence is incompletely understood. Most GPCR drugs bind a conserved orthosteric pocket, which can result in non-specificity, toxicity and clinical failure. Precision modalities including biased signaling and allosteric modulation could lead to GPCR therapeutics with improved efficacy and safety profiles. The rational design of precision therapies is, however, limited by the lack of high-resolution functional annotation of GPCR structures. Here we present a fast and general approach to rapidly build complete, high-resolution, multi-modal functional and allosteric maps of receptors. The approach, GPCR-MAPS, quantifies direct recruitment of proteins to a receptor and deconvolves the substantial effects of mutations on receptor expression. Applying GPCR-MAPS to the {beta}2 adrenergic receptor generates >150,000 phenotypic measurements, including the full activation functions for all possible amino acid substitutions (>7,500 unique variants) in a single experiment. The multi-modal maps provide numerous mechanistic insights and reveal a modular receptor architecture, with a core activation network surrounded by residues controlling quantitative parameters and bias. The maps also identify multiple allosteric surface pockets, including pockets bound by serendipitously discovered allosteric ligands and a novel pocket with no known ligands. The application of this approach across the superfamily of GPCRs will provide comparative maps of receptor mechanisms and a functional framework for the rational design of precision GPCR therapeutics.

systems biology↗

A pharmacological chaperone stabilizer rescues the expression of the vast majority of pathogenic variants in a G protein-coupled receptor

Reduced protein stability is the most frequent mechanism by which rare missense variants cause disease. A promising therapeutic avenue for treating destabilizing variants is pharmacological chaperones (PCs, also known as correctors or stabilizers), small molecules that bind to and stabilize target proteins. PCs have been approved as clinical treatments for specific variants, but protein energetics suggest their effects might be much more general. Here, we test this hypothesis for the first time by comprehensively quantifying PC efficacy for all missense variants in a human disease gene, the vasopressin 2 receptor (V2R), a G-protein coupled receptor in which loss-of-function variants cause nephrogenic diabetes insipidus (NDI). Strikingly, treatment with a PC rescues the expression of nearly all destabilized variants, with non-rescued variants identifying the drugs binding site. Our results provide proof-of-principle that a single small molecule can rescue destabilizing variants throughout a proteins structure. The application of this principle to other proteins should allow the development of effective therapies for many genetic diseases.

genetics↗

SUNi mutagenesis: scalable and uniform nicking for efficient generation of variant libraries

Multiplexed assays of variant effects (MAVEs) have made possible the functional assessment of all possible mutations to genes and regulatory sequences. A core pillar of the approach is generation of variant libraries, but current methods are either difficult to scale or not uniform enough to enable MAVEs at the scale of gene families or beyond. We present an improved method called Scalable and Uniform Nicking (SUNi) mutagenesis that combines massive scalability with high uniformity to enable cost-effective MAVEs of gene families and eventually genomes.

genomics↗